| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
|
| 2 |
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.
|
| 3 |
McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors[J]. Cancer Res, 2008, 68(9): 3389-3395.
|
| 4 |
Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis[J]. Lancet Oncol, 2011, 12(11): 1004-1012.
|
| 5 |
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014, 371(23): 2167-2177.
|
| 6 |
Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2018, 36(22): 2251-2258.
|
| 7 |
Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of Crizotinib versus chemotherapy in patients with advanced ALK-Positive non-small-cell lung cancer: Results from PROFILE 1014[J]. J Clin Oncol, 2016, 34(24): 2858-2865.
|
| 8 |
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in untreated ALK-positive Non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(9): 829-838.
|
| 9 |
Gainor JF, Tan DS, De Pas T, et al. Progression-free and overall survival in ALK-Positive NSCLC patients treated with sequential Crizotinib and Ceritinib[J]. Clin Cancer Res, 2015, 21(12): 2745-2752.
|
| 10 |
Watanabe S, Hayashi H, Okamoto K, et al. Progression-free and overall survival of patients with ALK Rearrangement-positive Non-small cell lung cancer treated sequentially with Crizotinib and Alectinib[J]. Clin Lung Cancer, 2016, 17(6): 528-534.
|
| 11 |
Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study[J]. Oncotarget, 2017, 8(13): 21903-21917.
|
| 12 |
Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-Rearranged lung cancer[J]. Cancer Discov, 2016, 6(10): 1118-1133.
|
| 13 |
Costa DB. Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling? [J]. Cell Cycle, 2017, 16(1): 19-20.
|
| 14 |
Tang SC, Nguyen LN, Sparidans RW, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar[J]. Int J Cancer, 2014, 134(6): 1484-1494.
|
| 15 |
Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib[J]. J Clin Oncol, 2011, 29(15): e443-445.
|
| 16 |
Ou SH, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC[J]. Ann Oncol, 2014, 25(2): 415-422.
|
| 17 |
Kim YH, Ozasa H, Nagai H, et al. High-dose Crizotinib for brain metastases refractory to standard-dose crizotinib[J]. J Thorac Oncol, 2013, 8(9): e85-86.
|
| 18 |
Peled N, Zach L, Liran O, et al. Effective Crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer[J]. J Thorac Oncol, 2013, 8(12): e112-113.
|
| 19 |
Wang S, Chen J, Xie Z, et al. Pulsatile Crizotinib treatment for brain metastasis in a patient with non-small-cell lung cancer[J]. J Clin Pharm Ther, 2017, 42(5): 627-630.
|
| 20 |
Rangachari D, Le X, Shea M, et al. Cases of ALK-Rearranged lung cancer with 5-year progression-free survival with Crizotinib as initial precision therapy[J]. J Thorac Oncol, 2017, 12(11): e175-e177.
|
| 21 |
Crinò L, Ahn MJ, De Marinis F, et al. Multicenter Phase Ⅱ Study of whole-body and intracranial activity with Ceritinib in patients with ALK-Rearranged non-Small-cell lung cancer previously treated with chemotherapy and Crizotinib: Results from ASCEND-2[J]. J Clin Oncol, 2016, 34(24): 2866-2873.
|
| 22 |
Yang JC, Ou SI, De Petris L, et al. Pooled systemic efficacy and safety data from the pivotal Phase Ⅱ studies (NP28673 and NP28761) of Alectinib in ALK-positive non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(10): 1552-1560.
|
| 23 |
Camidge DR, Kim DW, Tiseo M, et al. Exploratory Analysis of Brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials[J]. J Clin Oncol, 2018, 36(26): 2693-2701.
|
| 24 |
Johung KL, Yeh N, Desai NB, et al. Extended survival and prognostic factors for patients with ALK-Rearranged non-small-cell lung cancer and brain metastasis[J]. J Clin Oncol, 2016, 34(2): 123-129.
|
| 25 |
Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study[J]. Lancet Oncol, 2018, 19(12): 1654-1667.
|
| 26 |
Hida T, Seto T, Horinouchi H, et al. Phase Ⅱ study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9[J]. Cancer Sci, 2018, 109(9): 2863-2872.
|
| 27 |
Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F[J]. N Engl J Med, 2016, 374(1): 54-61.
|
| 28 |
Toyokawa G, Seto T. Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data[J]. Oncol Res Treat, 2015, 38(6): 291-298.
|
| 29 |
Yamaguchi N, Lucena-Araujo AR, Nakayama S, et al. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer[J]. Lung Cancer, 2014, 83(1): 37-43.
|
| 30 |
Tani T, Yasuda H, Hamamoto J, et al. Activation of EGFR Bypass Signaling by TGF-α Overexpression Induces AcquiredResistance to Alectinib in ALK-Translocated Lung Cancer Cells[J]. Mol Cancer Ther, 2016, 15(1): 162-171.
|
| 31 |
Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer[J]. Nat Med, 2014, 20(9): 1027-1034.
|
| 32 |
Li L, Wang Y, Peng T, et al. Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway[J]. Oncotarget, 2016, 7(23): 34442-34452.
|
| 33 |
Cuyàs E, Pérez-Sánchez A. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer[J]. Cell Cycle, 2016, 15(24): 3413-3418.
|
| 34 |
林采余，卢从化，潘永红，等. 水飞蓟宾增敏克唑替尼抑制间变性淋巴瘤激酶阳性非小细胞肺癌的作用及机制[J]. 中华肿瘤杂志，2017, 39(9): 650-656.
|
| 35 |
DiBonaventura MD, Wong W, Shah-Manek B, et al. Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA[J]. Onco Targets Ther, 2017, 11: 75-82.
|